Skyviews Life Science

Investor type Venture Capital
Founders Boris F. J. Collardi Jean-Pierre Aoun Stefan Catsicas

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 10
Average round size
info
The average size of a deal this fund participated in
$39M
Portfolio companies 8
Rounds per year 2.50
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Food and Beverage
  • Health Care
  • Life Science
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Skyviews Life Science:
Typical Co-investors
Skyviews Life Science is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Skyviews Life Science:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aetna Ventures Connecticut, Hartford, United States
Beijing Wojia Xinxi Zixun Zhongxin Beijing, China, Haidian
Bitclick GmbH -
Blue Ivy Ventures Boston, Massachusetts, United States
Breakwater Ventures Pennsylvania, United States, West Chester
Cain International England, London, United Kingdom
Japanese Organization for Medical Device Development Japan, Tokyo
KJS Ahluwalia Group India, Keonjhar, Odisha
Lezhong Investment Management China, Guangdong, Zhuhai
Maine Technology Institute Brunswick, Maine, United States
Rinkelberg Capital England, London, United Kingdom
Spectra Investments Brazil, São Paulo, Sao Paulo
The Kyoto Shinkin Bank Japan, Tokyo
The Thermo Companies -
UTEC Ventures Lima, Lima, Peru
WuXi PharmaTech China, Shanghai
YLZ Information Technology China, Fujian, Xiamen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

BCD Bioscience

$12M13 Apr 2022 Davis, California, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$43M21 Jul 2021 Cambridge, Massachusetts, United States

Aleph Farms

Food and Beverage
Green Consumer Goods
GreenTech
Nutrition
$105M07 Jul 2021 Rishon Lezion, Center District, Israel

Biotechnology
Life Science
Manufacturing
Medical
Therapeutics
$82M05 May 2021 South San Francisco, California, United States

MIRAI FOODS

Food and Beverage
$4M15 Mar 2021 Zurich, Switzerland

Ukko

Food and Beverage
Health Care
$40M27 Jan 2021 Palo Alto, California, United States

Agriculture
Biotechnology
$28M04 Jun 2020 London, England, United Kingdom

BCD Bioscience

$4M13 May 2020 Davis, California, United States

COMPASS Pathways

Biotechnology
Health Care
Life Science
Personal Health
Wellness
$80M27 Apr 2020 England
News
Vedanta Biosciences Raises $68M in Series D Financing

– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Skyviews Life Science?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: